Renal Medullary Carcinoma

(R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate, 26 base single stranded phosphodiester DNA oligonucleotide, 4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline, Aldesleukin ( PROLEUKIN ), Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex ( ONCOPHAGE ), Autologous renal cell tumor vaccine, Axitinib ( INLYTA ), Bevacizumab ( Equidacent, AVASTIN, Aybintio, MVASI ), Everolimus ( AFINITOR, VOTUBIA ), Genetically modified allogeneic (human) tumour cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM), Girentuximab ( RENCAREX ), HLA class I/II binding tumour associated peptides (ADF-APO-CCN-GUC-K67-MET-MMPMMPMUC-RGS), Human interleukin-2 (glycosylated tetrasaccharide, glycosylated trisaccharide and nonglycosylated) (inhalation use), Humanized anti-KSA monoclonal antibody-human interleukin-2 fusion protein, Interferon gamma 1b ( ACTIMMUNE, IMUKIN ), Iodine (131I) chimeric IgG monoclonal antibody cG250, N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate, Naptumomab estafenatox, Pazopanib hydrochloride ( VOTRIENT ), Recombinant human interleukin-21, Recombinant modified vaccinia Ankara expressing human 5T4, Siltuximab ( SYLVANT ), Sorafenib tosylate ( NEXAVAR ), Sunitinib malate ( SUTENT ), Talactoferrinum alfa, Temsirolimus ( TORISEL )